Goldman Jonathan
SEC insider (Form 3/4/5 filer). CIK 0002013869. Director at Avalo Therapeutics, Inc. (AVTX). 5 reported Form 4/5 transactions since Sep 2024; latest on Nov 14, 2025. Located in ROCKVILLE, MD.
Companies Goldman Jonathan has filed insider reports for
- Avalo Therapeutics, Inc. (AVTX): Director
Goldman Jonathan
CIK: 0002013869
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (40.0%)
Position reduction
Option Exercises (M)2 (40.0%)
Derivative conversions
Awards (A)1 (20.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AVTX
Avalo Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Nov 14, 2025AVTX
Avalo Therapeutics, Inc.
SaleDirect3.2K shares at avg. $14.30$45K - Nov 14, 2025AVTX
Avalo Therapeutics, Inc.
ExerciseDirect8.2K shares at avg. $9.88$81K - Nov 14, 2025AVTX
Avalo Therapeutics, Inc.
SaleDirect8.2K shares at avg. $14.35$118K - Jun 17, 2025AVTX
Avalo Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20.1K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
ExerciseDirect3.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Nov 14, 2025 | AVTX Avalo Therapeutics, Inc. | Sale | 3,167 | $14.30 | $45,288 | Direct |
| Nov 14, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise | 8,200 | $9.88 | $81,016 | Direct |
| Nov 14, 2025 | AVTX Avalo Therapeutics, Inc. | Sale | 8,200 | $14.35 | $117,649 | Direct |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise | 3,167 | - | - | Direct |
1-5 of 5 transactions